Showing results (71-80 of 80) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Plos Medicine|May 23, 2020
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trialsZoe Moodie, Stephen R Walsh, Fatima Laher, et al.Medrxiv : the Preprint Server for Health Sciences|May 5, 2021
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cellsKristen W Cohen, Susanne L Linderman, Zoe Moodie, et al.Cell Reports. Medicine|July 12, 2021
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cellsKristen W Cohen, Susanne L Linderman, Zoe Moodie, et al.Plos Medicine|March 19, 2024
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trialZoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, et al.The Lancet. HIV|June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trialLinda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.Biorxiv : the Preprint Server for Biology|June 2, 2021
Longitudinal immune dynamics of mild COVID-19 define signatures of recovery and persistenceAarthi Talla, Suhas V Vasaikar, Maria P Lemos, et al.Emerging Microbes & Infections|April 7, 2025
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trialsZoe Moodie, Shuying Sue Li, Elena E Giorgi, et al.The Journal of Infectious Diseases|June 27, 2022
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition RiskZoe Moodie, One Dintwe, Sheetal Sawant, et al.Science Translational Medicine|July 30, 2025
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trialK Rachael Parks, Zoe Moodie, Mary A Allen, et al.The New England Journal of Medicine|March 24, 2021
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in AdultsGlenda E Gray, Linda-Gail Bekker, Fatima Laher, et al.Pageof 8